Deutsche Bank’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.49M | Buy |
239,347
+1,559
| +0.7% | +$27.6K | ﹤0.01% | 1566 |
|
|
2026
Q1 | $4.51M | Hold |
237,788
| – | – | ﹤0.01% | 1346 |
|
|
2025
Q4 | $4.16M | Sell |
237,788
-32,096
| -12% | -$604K | ﹤0.01% | 1389 |
|
|
2025
Q3 | $5.58M | Buy |
269,884
+2,096
| +0.8% | +$50.8K | ﹤0.01% | 1262 |
|
|
2025
Q2 | $5.7M | Sell |
267,788
-159,831
| -37% | -$3.64M | ﹤0.01% | 1191 |
|
|
2025
Q1 | $8.25M | Sell |
427,619
-51,189
| -11% | -$1.03M | ﹤0.01% | 1062 |
|
|
2024
Q4 | $8.55M | Buy |
478,808
+81,130
| +20% | +$1.57M | ﹤0.01% | 1067 |
|
|
2024
Q3 | $8.71M | Buy |
397,678
+349,985
| +734% | +$4.89M | ﹤0.01% | 1056 |
|
|
2024
Q2 | $372K | Sell |
47,693
-23,833
| -33% | -$129K | ﹤0.01% | 2487 |
|
|
2024
Q1 | $296K | Sell |
71,526
-1,711
| -2% | -$6.8K | ﹤0.01% | 2618 |
|
|
2023
Q4 | $191K | Buy |
73,237
+7,887
| +12% | +$16.2K | ﹤0.01% | 2905 |
|
|
2023
Q3 | $122K | Buy |
65,350
+11,696
| +22% | +$22.3K | ﹤0.01% | 3061 |
|
|
2023
Q2 | $135K | Buy |
+53,654
| New | +$97.9K | ﹤0.01% | 3107 |
|
|
2022
Q2 | – | Sell |
-14,310
| Closed | -$35K | – | 4305 |
|
|
2022
Q1 | $35K | Sell |
14,310
-1,698
| -11% | -$4.28K | ﹤0.01% | 3942 |
|
|
2021
Q4 | $43K | Buy |
16,008
+850
| +6% | +$4.09K | ﹤0.01% | 3999 |
|
|
2021
Q3 | $76K | Buy |
15,158
+1,805
| +14% | +$13K | ﹤0.01% | 4004 |
|
|
2021
Q2 | $100K | Buy |
13,353
+13,344
| +148,267% | +$87.5K | ﹤0.01% | 4144 |
|
|
2021
Q1 | $0 | Buy |
+9
| New | +$58 | ﹤0.01% | 4659 |
|
|
2020
Q1 | – | Sell |
-1,961
| Closed | -$3K | – | 4777 |
|
|
2019
Q4 | $3K | Buy |
1,961
+1,761
| +881% | +$2.83K | ﹤0.01% | 4781 |
|
|
2019
Q3 | $0 | Sell |
200
-1,700
| -89% | -$2.3K | ﹤0.01% | 5237 |
|
|
2019
Q2 | $2K | Sell |
1,900
-9,600
| -83% | -$16.1K | ﹤0.01% | 5192 |
|
|
2019
Q1 | $21K | Buy |
+11,500
| New | +$18.9K | ﹤0.01% | 4781 |
|
|
2018
Q3 | – | Sell |
-23,400
| Closed | -$57K | – | 5543 |
|
|
2018
Q2 | $57K | Sell |
23,400
-36,437
| -61% | -$467K | ﹤0.01% | 4741 |
|
|
2018
Q1 | $771K | Buy |
59,837
+21,546
| +56% | +$269K | ﹤0.01% | 3464 |
|
|
2017
Q4 | $424K | Buy |
38,291
+1,219
| +3% | +$13.6K | ﹤0.01% | 3688 |
|
|
2017
Q3 | $465K | Buy |
37,072
+29,930
| +419% | +$388K | ﹤0.01% | 3470 |
|
|
2017
Q2 | $81K | Buy |
7,142
+1,964
| +38% | +$22.1K | ﹤0.01% | 4258 |
|
|
2017
Q1 | $67K | Buy |
5,178
+1,568
| +43% | +$18.1K | ﹤0.01% | 4107 |
|
|
2016
Q4 | $30K | Sell |
3,610
-2,439
| -40% | -$26K | ﹤0.01% | 4489 |
|
|
2016
Q3 | $54K | Buy |
6,049
+349
| +6% | +$2.52K | ﹤0.01% | 4190 |
|
|
2016
Q2 | $44K | Buy |
+5,700
| New | +$46.4K | ﹤0.01% | 4473 |
|
Other funds holding SMMT
BBA
Deutsche Bank's SMMT Position: Q2 2026 in Review
Deutsche Bank increased its Summit Therapeutics (SMMT) stake by 0.66% in Q2 2026, buying an estimated $27.6K and bringing the position to 239,347 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1566.
Deutsche Bank first reported a position in SMMT in Q2 2016 and has held it in 31 quarters since. The position peaked at $8.71M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.
- Deutsche Bank held 239,347 shares of Summit Therapeutics worth $3.49M as of Q2 2026.
- Deutsche Bank bought 1,559 Summit Therapeutics shares in Q2 2026, an estimated $27.6K.
- Summit Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1566 holding.
- Deutsche Bank first reported a position in Summit Therapeutics in Q2 2016 and has held it in 31 quarters since.
- Deutsche Bank's Summit Therapeutics position peaked at $8.71M in Q3 2024.
- 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.